Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Denis Chem Lab's Revenue for the
three
months ended in Jun. 2026 was ₹440 Mil. Denis Chem Lab's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹387 Mil.
Hence, Denis Chem Lab's Receivables Turnover for the
three
months ended in Jun. 2026 was 1.14.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Denis Chem Lab Receivables Turnover Related Terms
Denis Chem Lab Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Denis Chem Lab's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:537536 vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Denis Chem Lab's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denis Chem Lab Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Denis Chem Lab's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Denis Chem Lab's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denis Chem Lab (BOM:537536) has a Receivables Turnover of 1.14 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Denis Chem Lab and its competitors. According to the industry distribution chart, Denis Chem Lab ranks #495 out of 947 companies in the Drug Manufacturers industry, placing it in the top 52.3%.
Is Denis Chem Lab's Receivables Turnover too high?
Denis Chem Lab's current Receivables Turnover is 1.14. The Drug Manufacturers industry median Receivables Turnover is 5.08. Denis Chem Lab's value of 1.14 is 77.6% below this industry median. Based on the distribution chart, Denis Chem Lab ranks #495 out of 947 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Denis Chem Lab has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Denis Chem Lab's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Denis Chem Lab ranks #495 out of 947 companies for Receivables Turnover. This places Denis Chem Lab in the lower half of its industry. The industry median Receivables Turnover is 5.08. Denis Chem Lab's value of 1.14 is 77.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.08, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Denis Chem Lab's current Receivables Turnover of 1.14 is 77.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Denis Chem Lab and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Denis Chem Lab's current Receivables Turnover is 1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Denis Chem Lab stock overvalued right now?
Based on GuruFocus' analysis, Denis Chem Lab (BOM:537536) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹116.19, compared to a current price of ₹71.34 — trading 38.6% below its estimated fair value. The current Receivables Turnover is 1.14 and 77.6% below the Drug Manufacturers industry median of 5.08. Denis Chem Lab's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Denis Chem Lab (BOM:537536), the current Receivables Turnover is 1.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Denis Chem Lab (BOM:537536) Overvalued in 2026?
Based on GuruFocus' analysis, Denis Chem Lab stock appears to be undervalued.
The current stock price of ₹71.34 is trading 38.6% below its estimated GF Value™ of ₹116.19.
GuruFocus considers Denis Chem Lab to be Significantly Undervalued.
Key valuation signals for BOM:537536:
Receivables Turnover: 1.14
GF Value™: ₹116.19 vs. price of ₹71.34 (38.6% below fair value)
Industry Position: 77.6% below the Drug Manufacturers median (#495 of 947)
No single metric tells the full story. See the BOM:537536 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Denis Chem Lab Ltd is a pharmaceutical company involved in the manufacturing of pharmaceutical products. The company offers sterile intravenous injectables for human and veterinary use for different therapeutic areas. Its product portfolio includes antibiotic injections, diuretic injections, parenteral amino acid injections, plasma volume expanders, anti-pyretic Inj. irrigation solutions and dialysis solutions. The company has only one reportable segment which is Manufacturing, and Sales of Transfusion Solution in Bottles It generates its revenues through the sale of transfusion solution in bottles.
76GF Score
Get the complete analysis for BOM:537536
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:537536 has been successfully added to your 
